

Available online at www.sciencedirect.com



Tetrahedron Letters 47 (2006) 817-820

Tetrahedron Letters

New synthesis of 3-methoxy-4-substituted pyrazole derivatives

Bertrand Cottineau, Jacques Chenault and Gérald Guillaumet*

Institut de Chimie Organique et Analytique, UMR CNRS 6005, Université d'Orléans, BP 6759, 45067 Orléans Cedex 2, France Received 8 March 2005; revised 13 November 2005; accepted 15 November 2005

Abstract—A simple and efficient protocol for the synthesis of 3-methoxy-4-arylmethylene- and 3-methoxy-4-heteroarylmethylenepyrazoles has been developed. These derivatives are obtained *in one step* from alcohols 3 or 8a–b. © 2005 Elsevier Ltd. All rights reserved.

The pyrazole moiety is present in a wide variety of biologically active compounds.¹ Among them, Kess et al. have described a number of 3-hydroxy-4-benzylpyrazoles (Fig. 1), which represent a new class of antidiabetic compounds.² These pyrazoles seem to act as inhibitors of glucose renal reabsorption. The authors have described a wide number of derivatives with good hypoglycemic activities. In all cases, their syntheses proceeded in low yield from β -ketoesters (Fig. 1).

In the last few years, we have been interested in the reactivity and the biological activity of ethyl 3-hydroxy-1*H*pyrazole-4-carboxylate. During these studies, reactions on N1, O3 and C5 positions and the in vivo hypoglycemic activity of these derivatives have been described.³ In the present letter, we show a new and efficient synthesis of 4-arylmethylenepyrazole and 4-heteroarylmethylenepyrazole derivatives. The methodology employed was based on a Friedel–Crafts-type reaction between carbocation 1 and aromatic species (Scheme 1). We postulated that this intermediate could be easily obtained by dehydration of alcohol 3,⁴ compound synthesized in quantitative yield by reduction of the ester function of pyrazole $2.^3$



Figure 1. Structure of hypoglycemic pyrazoles.

0040-4039/\$ - see front matter @ 2005 Elsevier Ltd. All rights reserved. doi:10.1016/j.tetlet.2005.11.072

In order to examine the formation of carbocation 1 we decided to react pyrazolylmethanol 3 with nucleophilic species, such as an alcohol and a thiol.

Reactions were carried out with a catalytic quantity of camphorsulfonic acid using either dichloromethane or the alcohol as a solvent. This resulted in the formation of ether or thioether 4a-h in moderate to excellent yields (Scheme 2, Table 1).⁵

During these reactions, bispyrazolylmethane **5** was obtained as a by-product (Table 1). According to the synthesis of bisbenzopyrazolylalkane described by Miki and collaborators,⁶ we have proposed the following autocondensation mechanism. In acidic conditions, dehydration of pyrazolylmethanol **3** forms the intermediate **1**



Scheme 1. Reaction investigated for the synthesis of 4-benzylpyrazoles.



Scheme 2. Reagents and conditions: (a) $LiAlH_4$ (2 equiv), THF, rt, 2 h, 99%. (b) 4a–c ROH (solvent), CSA (0.1 equiv), rt, 1 h 4d–h RZH (3 equiv), CSA (0.1 equiv), CH₂Cl₂, rt, 1 h.

Keywords: Pyrazole; Benzylpyrazole; Friedel-Crafts.

^{*} Corresponding author. Tel.: +33 2 38 41 73 54; fax: +33 2 38 41 72 81; e-mail: gerald.guillaumet@univ-orleans.fr

Table 1.	Synthesis	of	ethers	and	thioether	4a-	-h

RXH	Solvent	Compound	4 (%) ^a	5 (%) ^a
EtOH	EtOH	4a	100	0
<i>i</i> PrOH	<i>i</i> PrOH	4b	100	0
tBuOH	tBuOH	4c	90	0
ОН	CH_2Cl_2	4d	71	25
Ме О ОН	CH ₂ Cl ₂	4e	50	46
CI	CH_2Cl_2	4f	60	34
ОН	CH_2Cl_2	4g	73	23
EtSH	CH_2Cl_2	4h	80	13

^a Isolated yield.

which reacts with another alcohol to give, after loss of formaldehyde, pyrazole **5** (Scheme 3).

After optimizing the conditions for the formation of carbocation 1, we investigated its reaction with aromatic and heteroaromatic species. To avoid the formation of bispyrazolylmethane 5, reactions were carried out by adding pyrazolylmethanol 3 very slowly to a solution of the aromatic and a catalytic quantity of camphorsulfonic acid in dichloromethane. These reactions produced pyrazoles $6a-i^7$ in yields varying from 50% to 80% (Scheme 4, Table 2). Structure of these derivatives was assigned based on NMR (1D and 2D). For pyrazoles 6a-d, the multiplicity of protons of phenyl rings indicates the substitution position. For compounds 6f-i, NOESY experiments were needed, these show a correlation between the CH₂ and H3' which confirms the substitution on C2 position of the heterocycle.



Scheme 3. Mechanism of the autocondensation of pyrazolylmethanol 3.



Scheme 4. Reagents and conditions: (a) ArH (3 equiv), CSA (0.1 equiv), CH_2Cl_2 , rt, 30 min.

Table 2.	Synthesis	of	3-methoxy-4-substituted	pyrazoles	6a-	—j
----------	-----------	----	-------------------------	-----------	-----	----



^a Isolated yield.

This reaction is compatible with activated benzene derivatives and neutral oxygen and nitrogen heteroaromatic species. In the case of less activated benzene derivatives, such as anisole and toluene, this reaction yielded pyrazole **5**.

To further diversify our synthetic library, we extended this reaction to substituted pyrazolylmethanol. Alcohols **8a** and **8b**⁸ were synthesized in good yields by the addition of organolithium species to aldehyde 7 (Scheme 5).⁹



Scheme 5. Reagents and conditions: (a) MnO_2 (10 equiv), $CHCl_3$, 20 h, rt, 99%. (b) RLi (2.5 equiv), THF, -30 °C, 3 h, (8a: R = Ph 87%; 8b: R = Bu 83%). (c) ArH (3 equiv), CSA (0.1 equiv), CH_2Cl_2 , rt, 30 min.

Table 3. Synthesis of pyrazoles 9a-d



^a Isolated yield.

As this aldehyde could not be obtained by the reduction of ester 2, this was carried out in quantitative yield by the reaction of alcohol 3 with MnO_2 . Reactions of these alcohols with aromatic and heteroaromatic species in the same conditions as described before gave the 4substituted pyrazoles **9a–d** in good yields (Table 3).¹⁰

In summary, we have developed a new and efficient synthesis of 3-methoxy-4-substituted pyrazoles 4, 6 and 9. These derivatives are synthesized in mild conditions starting from alcohols 3 and 8a-b.

References and notes

- 1. Elguero, J.; Goya, P.; Jagerovic, N.; Silva, A. M. S. Targets Heterocycl. Syst. 2002, 6, 52.
- Kees, K. L.; Fitzgerald, J. J., Jr.; Steiner, K. E.; Mattes, J. F.; Mihan, B.; Tosi, T.; Mondoro, D.; McCaleb, M. L. J. *Med. Chem.* **1996**, *39*, 3920.

- (a) Cottineau, B.; Chenault, J. *Synlett* **2002**, 769; (b) Cottineau, B.; Toto, P.; Marot, C.; Pipaud, A.; Chenault, J. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 2105.
- 4. Synthesis of compound 3: To a stirred suspension of LiAlH₄ (4.1 g, 108.4 mmol) in 30 mL of dry THF, cooled to 0 °C, was added slowly a solution of compound 2 (10 g, 54.2 mmol) in 50 mL of dry THF. The reaction mixture was stirred for 2 h at rt and cooled to 0 °C. Then, 4.1 mL of water, 4.1 mL of 15% NaOH solution and 12.3 mL of water were added successively. The resulting mixture was stirred for 1 h at rt and filtered off on Celite. The filtrate was dried over MgSO₄ and concentrated under vacuum to give a colourless oil (7.6 g, 99%). ¹H NMR (250 MHz, CDCl₃) δ 3.55 (s, 3H); 3.75 (s, 3H); 4.25 (s, 2H); 6.95 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 38.7, 56.2, 58.2, 105.4, 131.4, 161.3. MS: 143 5[M+H]⁺. IR (NaCl) 3100 cm⁻¹.
- 5. (a) Synthesis of compounds 4a-c, general procedure: To a stirred solution of CSA (23 mg, 0.1 mmol) in 5 mL of alcohol was added pyrazole 3 (140 mg, 1 mmol). The resulting mixture was stirred at rt for 1 h, then 15 mL of a saturated NaHCO₃ solution and 15 mL of CH₂Cl₂ were added. The organic layer was separated, dried over MgSO₄ and concentrated under vacuum to give a colourless oil. Synthesis of compounds 4d-h, general procedure: To a stirred solution of CSA (23 mg, 0.1 mmol) and alcohol or thiol (3 mmol) in 5 mL of CH₂Cl₂ was added pyrazole 3 (140 mg, 1 mmol). The resulting mixture was stirred at rt for 1 h, then 15 mL of a saturated NaHCO₃ solution and 15 mL of CH₂Cl₂ was added pyrazole 3 (140 mg, 1 mmol). The resulting mixture was stirred at rt for 1 h, then 15 mL of a saturated NaHCO₃ solution and 15 mL of CH₂Cl₂ were added. The organic layer was separated, dried over MgSO₄ and concentrated under vacuum to give a colourless oil.

(b) Spectral data for compounds 4a-h. Compound 4a: ¹H NMR (250 MHz, CDCl₃) δ 1.15 (t, J = 6.8 Hz, 3H); 3.44 (q, J = 6.8 Hz, 2H); 3.65 (s, 3H); 3.85 (s, 3H); 4.21 (s, 2H); 7.11 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 15.5; 39.2; 56.4; 61.5; 65.5; 102.7; 132.0; 162.0. MS: 172 [M+H]⁺. Compound 4b: ¹H NMR (250 MHz, CDCl₃) δ 1.12 (d, J = 6.2 Hz, 2H); 3.55–3.68 (m, 4H); 3.85 (s, 3H); 4.21 (s, 2H); 7.11 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 21.9; 38.5; 55.9; 58.4; 70.0; 102.6; 131.3; 161.3. MS: 185 [M+H]⁺. Compound 4c: ¹H NMR (250 MHz, CDCl₃) δ 1.23 (s, 9H); 3.66 (s, 3H); 3.87 (s, 3H); 4.18 (s, 2H); 7.12 (s,1H). ¹³C NMR (63 MHz, CDCl₃) δ 29.3; 40.4; 54.8; 57.7; 74.7; 105.1; 132.9; 162.8. MS: 199 [M+H]⁺. Compound 4d: ¹H NMR (250 MHz, CDCl₃) δ 2.39 (t, J = 2.35 Hz, 1H); 3.62 (s, 3H); 3.82 (s, 3H); 4.04 (d, J = 2.35 Hz, 2H); 4.29 (s, 2H); 7.11 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 37.6; 54.9; 55.1; 58.8; 73.1; 78.6; 99.8; 130.7; 160.6. MS: 181 [M+H]⁺. Compound 4e: ¹H NMR (250 MHz, CDCl₃) δ 1.37 (s, 3H); 1.44 (s, 3H); 3.59 (dd, J = 5.0 and 11.6 Hz, 1H); 3.65–3.80 (m, 5H); 3.90 (s, 3H); 4.05 (dd, J = 6.6, 8.2 Hz, 1H); 4.20– 4.25 (m, 1H); 4.28 (s, 2H); 7.17 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 23.7; 25.2; 37.3; 54.6; 58.5; 61.5; 64.3; 74.7; 100.7; 107.8; 130.3; 160.3. MS: 257 [M+H]⁺. Compound 4f: ¹H NMR (250 MHz, CDCl₃) & 1.57-1.81 (m, 4H); 3.38 (t, J = 6.1 Hz, 2H); 3.46 (d, J = 6.5 Hz, 2H); 3.63(s, 3H); 3.83 (s, 3H); 4.18 (s, 2H); 7.08 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 29.0; 31.5; 40.9; 47.0; 58.1; 63.3; 70.7; 104.2; 133.6; 163.7. MS: 232–234 [M+H]⁺. Compound **4g**: ¹H NMR (250 MHz, CDCl₃) δ 1.40–1.80 (m, 4H); 3.65 (s, 3H); 3.86 (s, 3H); 3.90-4.00 (m, 1H); 4.18 (s, 2H); 7.11 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 24.0; 33.0; 39.3; 56.6; 59.8; 80.8; 103.2; 132.0; 162.1. MS: 211 [M+H]⁺. Compound **4h**: ¹H NMR (250 MHz, CDCl₃) δ 1.23 (t, J = 7.3 Hz, 3H); 2.48 (q, J = 7.3 Hz, 2H); 3.47 (s, 2H); 3.68 (s, 3H); 3.88 (s, 3H); 7.06 (s, 1H). ¹³C NMR(63 MHz, CDCl₃) & 14.6; 23.0; 25.7; 39.0; 56.3; 102.2; 130.8; 161.4. MS: $187 [M+H]^+$.

- (a) Miki, Y.; Tomii, O.; Nakao, H.; Kubo, M.; Hachiken, H.; Takemura, S.; Ikeda, M. J. Heterocycl. Chem. 1988, 25, 327; (b) Miki, Y.; Nakamura, N.; Hachiken, H.; Takemura, S. J. Heterocycl. Chem. 1989, 26, 1739.
- 7. (a) Synthesis of compounds 6a-i, general procedure: To a stirred solution of CSA (23 mg, 0.1 mmol) and the aromatic (3 mmol) in 5 mL of CH₂Cl₂ was added slowly (1 h) pyrazole 3 (140 mg, 1 mmol) in 5 mL of CH_2Cl_2 . The resulting mixture was stirred at rt for 1 h, then 15 mL of a saturated NaHCO3 solution and 15 mL of CH₂Cl₂ were added. The organic layer was separated, dried over MgSO₄ and concentrated under vacuum. Compounds were purified by column chromatography on silica gel; (b) Spectral data for compounds 6a-i. Compound 6a: (white solid) mp: 118 °C ¹H NMR (250 MHz, CDCl₃) δ 3.55 (s, 5H); 3.75 (s, 6H); 3.77 (s, 3H); 3.90 (s, 3H); 6.64 (s, 2H); 6.88 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 15.5; 39.0; 55.4; 56.0; 56.4; 91.2; 105.3; 110.3; 130.5; 158.9; 159.7; 161.2. MS: 293 $[M+H]^+$. Compound **6b**: (colourless oil) ¹H NMR (250 MHz, CDCl₃) δ 3.56 (s, 2H); 3.63 (s, 3H); 3.75 (s, 3H); 3.78 (s, 3H); 3.89 (s, 3H); 6.38 (dd, J = 2.4 Hz, 8.1 Hz, 1H); 6.42 (d, J = 2.4 Hz, 1H); 6.81 (s, 1H); 7.0 (d, J = 8.1 Hz, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 20.7; 37.6; 55.2; 55.0; 97.4; 102.8; 103.2; 120.9; 128.8; 129.6; 156.9; 158.2; 160.3. MS: 263 $[M+H]^+$. Compound 6c: (white solid) mp: 102 °C ¹H NMR (250 MHz, CDCl₃) δ 3.60 (s, 2H); 3.66 (s, 3H); 3.92 (s, 3H); 6.77 (d, J = 8.3 Hz, 2H); 6.86 (s, 1H); 7.07 (d, J = 8.3 Hz, 2H); 8.53 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 27.8; 38.9; 56.8; 55.0; 106.0; 115.8; 129.8; 131.4; 132.7; 155.3; 161.6. MS: 219 [M+H]⁺ IR (KBr) 3000-3300 cm⁻¹. Compound **6d**: (white solid) mp: $180 \,^{\circ}\text{C}^{-1}\text{H}$ NMR (250 MHz, CDCl₃) δ 3.51 (s, 3H); 3.65 (s, 8H); 3.75 (s, 3H); 6.04 (s, 2H); 6.71 (s, 1H); 8.28 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 27.8; 39.2; 55.7; 56.4; 91.2; 105.3; 110.3; 130.5; 155.9; 158.7; 161.2. MS: 279 [M+H]⁺. IR (KBr) 3000–3300 cm⁻¹. Compound **6e**: (white solid) mp<40 °C ¹H NMR (250 MHz, CDCl₃) δ 3.57 (s, 3H); 3.78 (s, 2H); 3.93 (s, 3H); 6.78 (s, 1H); 6.90 (s, 1H); 7.00–7.15 (m, 2H); 7.27 (d, J = 7.5 Hz, 1H); 7.56 (d, J = 7.5 Hz, 1H); 8.23 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 16.2; 36.8; 54.3; 102.8; 109.3; 113.5; 117.2; 120.0; 125.4; 128.8; 134.6; 159.3. MS: 242 [M+H]⁺. IR (KBr) 3300 cm^{-1} . Compound **6f**: (white solid) mp<40 °C ¹H NMR (250 MHz, CDCl₃) δ 3.67 (s, 3H); 3.96 (s, 3H); 5.95 (m, 1H); 6.11 (m, 1H); 6.66 (m, 1H); 6.93 (s, 1H); 8.53 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 20.1; 38.0; 55.6; 102.4; 104.3; 107.2; 116.0; 129.7; 130.6; 160.4. MS: 192 [M+H]⁺. IR (KBr) 3333 cm⁻¹. Compound **6g**: (white solid) mp: 90 °C ¹H NMR (250 MHz, CDCl₃) δ 3.51 (s, 3H); 3.62 (s, 2H), 3.68 (s, 3H); 3.94 (s, 3H); 5.89 (m, 1H); 6.05 (m, 1H); 6.55 (m, 1H); 6.82 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 19.9; 34.0; 39.2; 56.5; 103.3; 106.8; 106.9; 121.7; 131.0; 132.2; 161.3. MS: 206 [M+H]⁺. Compound 6h: (colourless oil) ¹H NMR (250 MHz, CDCl₃) & 3.68 (s, 5H); 3.89 (s, 3H); 5.98 (m, 1H); 6.25 (m, 1H); 6.98 (s, 1H); 7.28 (m, 1H). ¹³C NMR (63 MHz. $CDCl_3$) δ 20.5; 38.1; 55.4; 100.5; 104.5; 109.5; 129.8; 140.3; 153.8; 160.5. MS: 193 [M+H]⁺. Compound 6i: (colourless oil) ¹H NMR (250 MHz, CDCl₃) δ 3.63 (s, 2H); 3.65 (s, 3H); 3.86 (s, 3H); 4.50 (s, 2H); 5.88 (d, J = 3.1 Hz, 1H); 6.12 (d, J = 3.1 Hz, 1H); 6.98 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 21.7; 39.1; 56.5; 57.7; 101.4; 106.4; 108.9; 131.1; 153.1; 155.0; 161.5. MS: 223 $[M+H]^+$. IR (KBr) 3150 cm⁻¹.
- 8. (a) Synthesis of alcohols 8a-b, general procedure: Under nitrogen, to a stirred solution of compound 7 (1.4 g, 10 mmol) in 30 mL of dry THF, was added at -30 °C the organolithium (30 mmol). The resulting mixture was stirred at -30 °C for 3 h then 30 mL of water was added. After extraction with ethyl acetate, the organic layer was dried over MgSO₄ and concentrated under vacuum. Then, the residue was purified by flash chromatography on silica gel to give a colourless oil; (b) Spectral data for compounds 8a-b. Compound 8a: ¹H NMR (250 MHz, CDCl₃) & 3.56 (s, 3H); 3.61 (s, 3H); 5.31 (s, 1H); 6.84 (s, 1H); 7.23–7.42 (m, 5H). ¹³C NMR (63 MHz, CDCl₃) δ 38.9; 56.2; 73.9; 107.6; 126.5; 127.2; 128.3; 130.6; 142.5; 161.0. MS: 219 [M+H]⁺. Compound 8b: ¹H NMR (250 MHz, CDCl₃) δ 0.80 (t, J = 6.9 Hz, 3H); 1.13–1.37 (m, 4H); 1.52–1.83 (m, 2H); 3.64 (s, 3H); 3.81 (s, 3H); 4.10 (t, J = 6.9 Hz, 1H); 7.0 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 14.1; 22.6; 28.2; 36.1; 38.9; 56.1; 72.1; 106.8; 129.8; 161.5. MS: 199 [M+H]⁺.
- 9. Synthesis of aldehyde 7. To a stirred solution of alcholol 3 (1.4 g, 10 mmol) in 40 mL of CHCl₃ was added MnO₂ (8.9 g, 100 mmol). The resulting mixture was stirred at rt for 20 h and filtered off, the filtrate was dried over MgSO₄ and concentrated under vacuum to give a slighly yellow solid (140 mg, 99%). ¹H NMR (250 MHz, CDCl₃) δ 3.74 (s, 3H); 3.94 (s, 3H); 7.64 (s, 1H); 9.67 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 40.3; 56.6; 109.6; 134.4; 164.0; 183.2 MS: 141 [M+H]⁺. IR (KBr) 1734 cm⁻¹.
- 10. (a) Synthesis of compounds **9a–d**, general procedure: To a stirred solution of CSA (0.1 mmol) and the aromatic (3 mmol) in 5 mL of CH₂Cl₂ was added slowly (1 h) pyrazole **8** (1 mmol) in 5 mL of CH₂Cl₂. The resulting mixture was stirred at rt for 1 h, then 15 mL of a saturated NaHCO₃ solution and 15 mL of CH₂Cl₂ were added. The organic layer was separated, dried over MgSO₄ and concentrated under vacuum. Compounds were purified by column chromatography on silica gel.

(b) Spectral data for compounds 9a-d. Compound 9a: (white solid) mp: 78 °C ¹H NMR (250 MHz, CDCl₃) δ 3.58 (s, 6H); 3.65 (s, 3H); 3.75 (s, 3H); 3.84 (s, 3H); 5.84 (s, 1H); 6.13 (s, 2H); 6.99 (s, 1H); 7.08–7.15 (m, 5H). ¹³C NMR (63 MHz, CDCl₃) δ 32.9; 38.8; 55.2; 55.9; 56.2; 91.9; 106.4; 114.8; 124.8; 127.5; 132.1; 144.9; 158.8; 159.8; 161.6. MS: $369 [M+H]^+$. Compound **9b**: (white solid) mp: 92 °C ¹H NMR (250 MHz, CDCl₃) δ 3.63 (s, 3H); 3.85 (s, 3H); 5.44 (s, 1H); 6.67–6.69 (m, 1H); 6.71 (s, 1H); 6.95–7.02 (m, 1H); 7.11–7.34 (m, 8H); 7.97 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) *δ* 37.2; 39.0; 56.3; 108.5; 111.1; 119.4; 120.0; 122.1; 123.2; 126.2; 126.9; 128.3; 128.4; 131.4; 136.9; 144.1; 160.9. MS: 318 $[M+H]^+$ IR (KBr) 3315 cm⁻¹. Compound 9c: (white solid) mp: 52 °C ¹H NMR (250 MHz, CCl₃) δ 0.82 (t, *J* = 6.9 Hz, 3H); 1.10–1.31 (m, 4H); 1.85–2.12 (m, 2H); 3.63 (s, 3H); 3.77 (s, 9H); 3.86 (s, 3H); 4.41 (dd, J = 6.9, 9.42 Hz, 1H); 6.13 (s, 2H); 6.96 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 14.1; 22.7; 28.5; 30.5; 33.2; 38.7; 55.1; 55.8; 56.2; 91.5; 109.3; 113.7; 130.6; 159.2; 159.3; 161.2. MS: $349 [M+H]^+$. Compound **9d**: (white solid) mp: $45 \degree C$ ¹H NMR (250 MHz, CDCl₃) δ 0.83–0.88 (m, 3H); 1.25– 1.35 (m, 4H); 1.93–2.05 (m, 2H); 3.59 (s, 3H); 3.91 (s, 3H); 4.03 (t, J = 7.7 Hz, 1H); 6.82 (s, 1H); 6.96 (d, J = 2.5 Hz, 1H); 7.03–7.17 (m, 2H); 7.28 (d, J = 7.8 Hz, 1H); 7.59 (d, J = 7.85 Hz, 1H); 8.26 (s, 1H). ¹³C NMR (63 MHz, CDCl₃) δ 14.1; 22.7; 30.3; 31.1; 35.6; 38.7; 56.2; 109.8; 111.2; 119.0; 119.6; 120.1; 121.1; 126.9; 129.9; 136.6; 161.1. MS: 298 $[M+H]^+$. IR (KBr) 3305 cm⁻¹.